Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial

Song, YQ; Zhou, H; Zhang, HL; Liu, W; Shuang, YR; Zhou, KS; Lv, FF; Xu, H; Zhou, JF; Li, W; Wang, HQ; Zhang, HY; Huang, HW; Zhang, QY; Xu, W; Ge, Z; Xiang, Y; Wang, SY; Gao, D; Yang, SE; Lin, JY; Wang, L; Zou, LQ; Zheng, MF; Liu, J; Shao, ZH; Pang, Y; Xia, RX; Chen, ZD; Hou, M; Yao, HX; Feng, R; Cai, Z; Zhang, MZ; Ran, WH; Liu, L; Zeng, S; Yang, W; Liu, P; Liang, AB; Zuo, XL; Zou, QF; Ma, JX; Sang, W; Guo, Y; Zhang, W; Cao, YQ; Li, Y; Feng, JF; Du, X; Zhang, XH; Zhao, HG; Zhou, H; Yu, J; Sun, X; Zhu, J; Qiu, LG

Qiu, LG (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood DiseasesHosp, Natl Clin Res Ctr Hematol Disorders, State Key Lab Expt Hematol, Tianjin, Peoples R China.; Zhu, J (corresponding author), Peking Univ Canc Hosp & Inst, Dept Lymphoma, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.

ADVANCES IN THERAPY, 2021; 38 (4): 1889

Abstract

Introduction Patients with diffuse large B-cell lymphoma (DLBCL) have limited access to rituximab. IBI301 is a recombinant chimeric murine/human anti-......

Full Text Link